M. Berger

S. Redline, L. Siminoff, E. Larkin, 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cells

T. Bonfield, M. Berger, A. Saadane, 2011, Journal of Inflammation.

Elastin and collagen degradation products in urine of patients with cystic fibrosis.

M. Konstan, H. Dorkin, G. Snider, 1995, American journal of respiratory and critical care medicine.

Parthenolide Inhibits IκB Kinase, NF-κB Activation, and Inflammatory Response in Cystic Fibrosis Cells and Mice

Jingfeng Li, J. DiDonato, M. Berger, 2007 .

Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis.

M. Konstan, P. Burfeind, T. Bonfield, 1995, American journal of respiratory cell and molecular biology.

Inflammatory mediators in cystic fibrosis lung disease.

M. Berger, 2002, Allergy and asthma proceedings.

Intravenous gamma-globulin therapy in bronchial asthma.

H. Schwartz, M. Berger, 2002, Allergy and asthma proceedings.

Role of anti-receptor autoantibodies in pathophysiology of scleroderma.

V. Steen, M. Berger, 2017, Autoimmunity reviews.

Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens

M. Berger, A. Chouksey, K. Duff, 2005, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

Optimizing IgG Therapy in Chronic Autoimmune Neuropathies: A Hypothesis Driven Approach

Jeffrey A. Allen, M. Berger, 2015, Muscle & nerve.

Subcutaneous immunoglobulin: opportunities and outlook

H. Ochs, M. Sturzenegger, R. Shapiro, 2009, Clinical and experimental immunology.

Individualized immunoglobulin therapy in chronic immune‐mediated peripheral neuropathies*

Jeffrey A. Allen, L. Querol, R. Hadden, 2018, Journal of the peripheral nervous system : JPNS.

Primary immune deficiency diseases as unrecognized causes of chronic respiratory disease.

E. Schulman, M. Berger, D. Cameron, 2017, Respiratory medicine.

Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection.

R. Stern, M. Konstan, J. Schreiber, 1995, The Journal of infectious diseases.

Higher Doses of Subcutaneous IgG Reduce Resource Utilization in Patients with Primary Immunodeficiency

E. Haddad, Elie Haddad, E. Wang, 2011, Journal of Clinical Immunology.

New Frontiers in Subcutaneous Immunoglobulin Treatment

M. Sturzenegger, B. Ritchie, M. Stein, 2011, Biologics in therapy.

Altered respiratory epithelial cell cytokine production in cystic fibrosis.

M. Konstan, T. Bonfield, M. Berger, 1999, The Journal of allergy and clinical immunology.

Functional IL-10 Deficiency in the Lung of Cystic Fibrosis (cftr−/−) and IL-10 Knockout Mice Causes Increased Expression and Function of B7 Costimulatory Molecules on Alveolar Macrophages1

T. Bonfield, M. Berger, J. Chmiel, 2002, The Journal of Immunology.

Inflammation in the lung in cystic fibrosis

M. Berger, 1991, Clinical Reviews in Allergy.

Role of IL-10 deficiency in excessive nuclear factor-kappaB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice.

M. Berger, A. Saadane, J. Šoltys, 2005, The Journal of allergy and clinical immunology.

Enhancement by Tumor Necrosis Factor-α of Fcα Receptor Expression and IgA-Mediated Superoxide Generation and Killing of Pseudomonas aeruginosa by Polymorphonuclear Leukocytes

I. Krukovets, M. Berger, R. Hostoffer, 1994 .

Subcutaneous IgG in neurologic diseases.

M. Berger, 2014, Immunotherapy.

Functional differences between the 40 kDa and 50 to 70 kDa IgG Fc receptors on human neutrophils revealed by elastase treatment and antireceptor antibodies.

M. Berger, M. Tosi, 1988, Journal of immunology.

Complement receptors.

M. Frank, M. Berger, I. Gaither, 1981, Clinical immunology reviews.

Safety, Efficacy, and Pharmacokinetics of Flebogamma® 5% [Immune Globulin Intravenous (Human)] for Replacement Therapy in Primary Immunodeficiency Diseases

M. Berger, P. Pinciaro, Flebogamma, 2004, Journal of Clinical Immunology.

Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice.

M. Konstan, H. Lester Kirchner, M. Berger, 2002, American journal of respiratory and critical care medicine.

Monocyte induction of IL-10 and down-regulation of IL-12 by iC3b deposited in ultraviolet-exposed human skin.

Y. Yoshida, K. Cooper, M. Berger, 1998, Journal of immunology.

A quantitative analysis of C3 binding to O-antigen capsule, lipopolysaccharide, and outer membrane protein of E. coli 0111B4.

K. Joiner, M. Frank, L. Leive, 1984, Journal of immunology.

A Multicenter, Prospective, Open Label, Historically Controlled Clinical Trial to Evaluate Efficacy and Safety in Primary Immunodeficiency Diseases (PID) Patients of Flebogamma® 5% DIF, the Next Generation of Flebogamma®

M. Berger, T. F. 5. D. Investigators, 2007, Journal of Clinical Immunology.

Goals of therapy in antibody deficiency syndromes.

M. Berger, 1999, The Journal of allergy and clinical immunology.

Dosage of intravenously administered immune globulin and dosing interval required to maintain target levels of immunoglobulin G in low birth weight infants.

A. Fanaroff, R. Kliegman, M. Berger, 1989, The Journal of pediatrics.

Intravenous and standard immune serum globulin preparations interfere with uptake of 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity.

M. Berger, C. Y. Brown, C. Y. Brown, 1985, Clinical immunology and immunopathology.

Localization of complement component 3 on Streptococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule

K. Joiner, E. Brown, M. Berger, 1983, Infection and immunity.

Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology.

Kathleen C. Williams, J. Orange, P. Yong, 2010, Clinical immunology.

Erratum: Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation (American Journal of Respiratory and Critical Care Medicine (1994) 150 (448-454))

M. Konstan, M. Berger, K. A. Hilliard, 1995 .

in Ultraviolet-Exposed Human Skin Down-Regulation of IL-12 by iC3b Deposited Monocyte Induction of IL-10 and

K. Cooper, M. Berger, K. Kang, 2013 .

Ultraviolet-Exposed Human Skin Down-Regulation of IL-12 by iC 3 b Deposited Monocyte Induction of IL-10 and Hammerberg and

Y. Yoshida, K. Cooper, M. Berger, 1998 .

IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG.

D. Cornblath, O. Mielke, T. Harbo, 2018, Immunotherapy.

Subcutaneous administration of IgG.

M. Berger, 2008, Immunology and allergy clinics of North America.

Subcutaneous immunoglobulin replacement in primary immunodeficiencies.

M. Berger, 2004, Clinical immunology.

Increased expression of complement decay-accelerating factor during activation of human neutrophils.

M. Berger, M. Medof, 1987, The Journal of clinical investigation.

Complement deficiency and neutrophil dysfunction as risk factors for bacterial infection in newborns and the role of granulocyte transfusion in therapy.

M. Berger, 1990, Reviews of infectious diseases.

Impaired Surface Membrane Expression of C3bi but Not C3b Receptors on Neonatal Neutrophils

M. Bruce, M. Berger, K. Medvik, 1987, Pediatric Research.

Another new mechanism of action of IGIV.

M. Berger, 2011, Clinical immunology.

Antibodies to vaccine antigens in pooled polyclonal human IgG products

M. Berger, 2018, Transfusion.

Tissue-Specific Fc γ and Complement Receptor Expression by Alveolar Macrophages Determines Relative Importance of IgG and Complement in Promoting Phagocytosis of Pseudomonas aeruginosa

M. Konstan, J. Schreiber, M. Berger, 1994, Pediatric Research.

Circulating immune complexes and glomerulonephritis in a patient with congenital absence of the third component of complement.

M. Frank, C. Wilson, J. Balow, 1983, The New England journal of medicine.

Adverse effects of IgG therapy.

M. Berger, 2013, The journal of allergy and clinical immunology. In practice.

Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-kappa B activation, cytokine secretion, and persistent lung inflammation.

M. Berger, A. Saadane, J. Šoltys, 2006, The Journal of allergy and clinical immunology.

Internalization of type 1 complement receptors and de novo multivesicular body formation during chemoattractant-induced endocytosis in human neutrophils.

J. August, A. Tartakoff, E. Wetzler, 1994, The Journal of clinical investigation.

Therapeutic Human IgG Preparations Contain Mixture of HLA Antibodies to Native HLA Antigens and Cryptic Epitopes With Little Clinical Significance

C. Ensor, M. Spycher, M. Berger, 2018, Transplantation.

Intracellular sites for storage and recycling of C3b receptors in human neutrophils.

A. Tartakoff, J. Turner, E. Wetzler, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation.

R. Gale, H. Lazarus, M. Berger, 2017, Blood reviews.

Association of ARF and Rabs with complement receptor Type‐1 storage vesicles in human neutrophils

M. Berger, Anoopa Kumar, Subhendu Chaudhuri, 2001, Journal of leukocyte biology.

Disseminated Histoplasma capsulatum in a patient with hyper IgM immunodeficiency.

J. Schreiber, M. Berger, R. Hostoffer, 1994, Pediatrics.

Isolation and characterization of complement receptor type 1 (CR1) storage vesicles from human neutrophils using antibodies to the cytoplasmic tail of CR1.

A. Kumar, E. Wetzler, M. Berger, 1997, Blood.

IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice.

M. Konstan, T. Bonfield, D. Dawson, 1999, American journal of respiratory and critical care medicine.

Immunoglobulin replacement therapy by slow subcutaneous infusion.

A. Fauci, M. Berger, T. Cupps, 1980, Annals of internal medicine.

127 – The Complement System of the Fetus and Newborn

M. Berger, 2017 .

Complement and Complement Reactions

H. Colten, O. Götze, P. Schneider, 1988 .

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy

J. Orange, B. Grimbacher, R. Wasserman, 2012, Clinical and experimental immunology.

Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation.

M. Konstan, M. Berger, M W Konstan, 1994, American journal of respiratory and critical care medicine.

Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation.

H. Lazarus, M. Berger, D. Sokos, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Human neutrophils increase expression of C3bi as well as C3b receptors upon activation.

Berger, Michael, J. O’Shea, 1984, The Journal of clinical investigation.

Secretory vesicles are the intracellular reservoir of complement receptor 1 in human neutrophils.

W. Kroeze, L. Kjeldsen, N. Borregaard, 1994, Journal of immunology.

Incidence of Infection is Inversely Related to Steady-State (Trough) Serum IgG Level in Studies of Subcutaneous IgG in PIDD

M. Berger, 2011, Journal of Clinical Immunology.

Mycobacterium tuberculosis 19-kDa Lipoprotein Promotes Neutrophil Activation1

C. Harding, W. Boom, C. Neufert, 2001, The Journal of Immunology.

A randomized double-blind trial

P. Korenblat, R. Sorensen, C. Roifman, 2003 .

Mechanism of priming of human neutrophils by a soluble lymphoblastoid cell factor.

J. Palmblad, A. Cross, J. Sadoff, 1985, Journal of immunology.

Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: report of a pilot study.

A. Fanaroff, R. Kliegman, M. Berger, 1989, The Journal of pediatrics.

Increased Fc alpha R expression and IgA-mediated function on neutrophils induced by chemoattractants.

I. Krukovets, M. Berger, R. Hostoffer, 1993, Journal of immunology.

Inflammatory mechanisms in cystic fibrosis lung disease

M. Berger, 2017 .

Safety and efficacy of Home-Based Subcutaneous Immunoglobulin G in Elderly Patients with Primary Immunodeficiency Diseases

A. Koterba, M. Stein, M. Berger, 2011, Postgraduate medicine.

Improved Quality of Life, Immunoglobulin G Levels, and Infection Rates in Patients with Primary Immunodeficiency Diseases during Self-Treatment with Subcutaneous Immunoglobulin G

G. Bergman, M. Berger, Elyse Murphy, 2010, Southern medical journal.

Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency Diseases

H. Ochs, Sudhir Gupta, U. Nicolay, 2006, Journal of Clinical Immunology.

Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.

P. Korenblat, R. Sorensen, C. Roifman, 2003, International immunopharmacology.

Targeted immunoglobulin therapy for the prevention of neonatal infections.

R. Kliegman, M. Berger, D. Clapp, 1990, Reviews of infectious diseases.

Clinical Experience With an L-Proline–Stabilized 10 % Intravenous Immunoglobulin (Privigen®): Real-Life Effectiveness and Tolerability

P. Soler-Palacín, M. Dorsey, M. Rojavin, 2014, Journal of Clinical Immunology.

Safety of L-proline as a stabilizer for immunoglobulin products

K. Sullivan, V. Shashi, E. Lohrmann, 2012, Expert review of clinical immunology.

L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use.

M. Berger, 2011, Immunotherapy.

Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules

K. Joiner, E. Brown, M. Frank, 1983, Infection and immunity.

Cytotoxicity of human serum for Leishmania donovani amastigotes: antibody facilitation of alternate complement pathway-mediated killing

M. Meltzer, D. Hoover, M. Oppenheim, 1985, Infection and immunity.

Biotinylation of human C3.

M. Frank, M. Berger, C. Hammer, 1982, Molecular immunology.

Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies

C. Lin, D. Mccallus, M. Berger, 2013, Journal of the peripheral nervous system : JPNS.

Assessment of protein antibody response in patients with suspected immune deficiency.

M. Berger, A. Chouksey, 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease

A N N Gardulf, R. Shapiro, M. Stein, 2015, Clinical and experimental immunology.

Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose

M. Berger, 2011, Current opinion in allergy and clinical immunology.

High-dose immunoglobulin replacement therapy by slow subcutaneous infusion during pregnancy.

A. Fauci, M. Berger, T. Cupps, 1982, JAMA.

Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease

A N N Gardulf, R. Shapiro, M. Stein, 2015, Clinical and experimental immunology.

From Subcutaneous to Intravenous Immunoglobulin and Back

E. Stiehm, E. R. Stiehm, M. Berger, 2014 .

A flow-cytometric method for the quantitative analysis of intracellular and surface membrane antigens.

A. Tartakoff, J. Turner, M. Berger, 1989, Methods in cell biology.

Chronic Inflammation in the Cystic Fibrosis Lung: Alterations in Inter- and Intracellular Signaling

M. Berger, J. Chmiel, D. Nichols, 2008, Clinical reviews in allergy & immunology.

Immunologic Challenges in Small Bowel Transplantation

K. Abu-Elmagd, D. Farmer, M. Berger, 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Native C3 does not bind to the C3b receptor (CR1) of human blood B lymphocytes or alter immunoglobulin synthesis.

T. Fleisher, M. Berger, 1983, Journal of immunology.

Using Elisa to evaluate complement activation by reference biomaterials

M. Sefton, M. Berger, B. Broxup, 1994 .

Modulation of human B cell immunoglobulin secretion by the C3b component of complement.

G. Tsokos, J. Balow, M. Berger, 1984, Journal of immunology.

Complement-Mediated Phagocytosis

M. Berger, 1998 .

Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.

James F. Jones, K. Edwards, C. Dekker, 2013, Vaccine.

Variability in Intravenous Immunoglobulin G Regimens for Autoimmune Neuromuscular Disorders

M. Berger, P. Riley, Linda Rodden, 2013, Postgraduate medicine.

In vitro evaluation of cytomegalovirus‐specific hyperimmune globulins vs. standard intravenous immunoglobulins

S. Miescher, D. Snydman, P. Lieby, 2015, Vox sanguinis.

Chronic Treatment With P2‐Purinergic Receptor Agonists Induces Phenotypic Modulation of the HL‐60 and U937 Human Myelogenous Leukemia Cell Lines

Melvin Berger, D. S. Cowen, G. Dubyak, 1991, Journal of leukocyte biology.

Deficient total cell content of CR3 (CD11b) in neonatal neutrophils.

M. Berger, M. Tosi, N. Abughali, 1994, Blood.

Clinical Experience With an L-Proline–Stabilized 10 % Intravenous Immunoglobulin (Privigen®): Real-Life Effectiveness and Tolerability

P. Soler-Palacín, M. Dorsey, M. Rojavin, 2014, Journal of Clinical Immunology.

Management of primary antibody deficiency with replacement therapy: summary of guidelines.

L. Notarangelo, C. Roifman, M. Berger, 2008, Immunology and allergy clinics of North America.

Bioavailability of IgG Administered by the Subcutaneous Route

J. Orange, J. Sleasman, S. Jolles, 2012, Journal of Clinical Immunology.

Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.

M. Rojavin, M. Berger, P. Kiessling, 2011, Clinical immunology.

Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER): Study Design and Progress Update (P2.269)

S. Ajroud‐Driss, R. Lewis, M. Pasnoor, 2016 .

Conversion from Intravenous to Subcutaneous Immunolgobulin Therapy: Relationship Between Dose, Serum Trough IgG Concentration and Infection Rate in Patients with Primary Immune Deficiency Diseases

H. Ochs, M. Berger, 2006 .

Efficient Utilization of IgG for Antibody Replacement Therapy.

M. Berger, 2015, The journal of allergy and clinical immunology. In practice.

Intramuscular versus intravenous immunoglobulin replacement therapy and measurement of immunoglobulin levels during immunoglobulin replacement therapy.

P. Lieberman, M. Berger, 2013, The journal of allergy and clinical immunology. In practice.

Bioavailability of IgG Administered by the Subcutaneous Route

J. Orange, J. Sleasman, S. Jolles, 2012, Journal of Clinical Immunology.

A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously.

M. Berger, A. Chouksey, J. Poll, 2009, The Journal of allergy and clinical immunology.

Increased frequency of infections at the end of the IVIG dosing cycle: effect characterization from three Phase III studies

M. Rojavin, M. Berger, J. Baggish, 2012 .

Pharmacokinetic Modeling Predicts Different IgG Exposures Using Different IVIG-Scig Dose Conversion Factors In Patients With Primary Immune Deficiency

J. Edelman, M. Rojavin, J. Sidhu, 2014 .

Hereditary angioedema C1-esterase inhibitor replacement therapy and coexisting autoimmune disorders: findings from a claims database

H. Farkas, D. Supina, M. Fridman, 2020, Allergy, Asthma & Clinical Immunology.

Lack of binding of human C3, in its native state, to C3b receptors.

M. Frank, M. Berger, C. Hammer, 1981, Journal of immunology.

Calcium requirements for increased complement receptor expression during neutrophil activation.

D. Birx, J. O’Shea, A. Cross, 1985, Journal of immunology.

Allergic bronchopulmonary aspergillosis and common variable hypogammaglobulinemia in an adult male patient: case report.

H. Schwartz, M. Berger, R. Hostoffer, 1996, Journal of Allergy and Clinical Immunology.

Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology

Melvin Berger, M. Konstan, Michael W. Konstan, 1997, Pediatric pulmonology.

Clinical Assessment of Serious Adverse Events in Children Receiving 2009 H1N1 Vaccination

J. Sejvar, K. Edwards, C. Dekker, 2013, The Pediatric infectious disease journal.

Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice.

Jingfeng Li, J. DiDonato, M. Berger, 2007, American journal of respiratory cell and molecular biology.

Higher Doses of Subcutaneous IgG Reduce Resource Utilization in Patients with Primary Immunodeficiency

E. Haddad, E. Wang, M. Berger, 2011, Journal of Clinical Immunology.

Immunoregulatory effects of C3 and its major cleavage fragments.

T. Fleisher, M. Berger, 1984, Clinical immunology and immunopathology.

Intracellular storage and regulated plasma membrane expression of human complement receptor type 1 in rat basophil leukemia cell transfectants.

A. Kumar, C. Jost, E. Wetzler, 1998, Blood.

Intracellular degradation of the complement C3b/C4b receptor in the absence of ligand.

A. Tartakoff, J. Turner, M. Berger, 1988, The Journal of biological chemistry.

Dosing Alternatives in Subcutaneous Immunoglobulin Therapy

M. Berger, 2012 .

Enhancement by tumor necrosis factor-alpha of Fc alpha receptor expression and IgA-mediated superoxide generation and killing of Pseudomonas aeruginosa by polymorphonuclear leukocytes.

I. Krukovets, M. Berger, R. Hostoffer, 1994, The Journal of infectious diseases.

Optimizing immunoglobulin G therapy in chronic autoimmune neuropathies

M. Berger, 2014, Clinical and experimental immunology.

Acute deterioration of pulmonary function in cystic fibrosis illustrating the association of atopy and allergic bronchopulmonary aspergillosis with the underlying disease.

D. Birx, R. Summers, M. Berger, 1984, Annals of allergy.

Complement-mediated serum cytotoxicity for Leishmania major amastigotes: killing by serum deficient in early components of the membrane attack complex.

M. Meltzer, D. Hoover, M. Berger, 1985, Journal of immunology.

Killing of Leishmania tropica amastigotes by factors in normal human serum.

M. Meltzer, D. Hoover, C. Nacy, 1984, Journal of immunology.

Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase.

M. Hershfield, R. Sorensen, Y. Levy, 1988, The Journal of pediatrics.

Improved Quality of Life, Immunoglobulin G Levels, and Infection Rates in Patients with Primary Immunodeficiency Diseases during Self-Treatment with Subcutaneous Immunoglobulin G

G. Bergman, M. Berger, Elyse Murphy, 2010, Southern medical journal.

Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.

James F. Jones, K. Edwards, C. Dekker, 2013, Vaccine.

Adverse effects of IgG therapy.

M. Berger, 2013, The journal of allergy and clinical immunology. In practice.

Carimune NF Liquid is a Safe and Effective Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency Diseases

C. Cunningham-Rundles, F. Bonilla, J. Bichler, 2007, Journal of Clinical Immunology.

Isolation and Characterization of Complement Receptor Type 1 ( CR 1 ) Storage Vesicles From Human Neutrophils Using Antibodies to the Cytoplasmic Tail of CR 1

E. Wetzler, M. Berger, Anoop Kumar, 1997 .

The response to intravenous immunoglobulin replacement therapy in patients with asthma with specific antibody deficiency.

H. Schwartz, M. Berger, R. Hostoffer, 2006, Allergy and asthma proceedings.

Third component of human complement: C3.

M. Berger, 1990, Methods in enzymology.